Group I p21-activated kinase (PAK) inhibitor (IC50 = 2.5 μM at PAK1). Targets the autoregulatory mechanism and promotes the inactive conformation of PAKs. Inhibits Pak1-mediated signaling in vivo; potential anti-tumor agent. Negative control PIR 3.5 (Cat. No. 4212) available.